GRAIL unveils validation data of its early-detection multi-cancer test
Category: #headlines  By Anchal Solanki  Date: 2020-03-31
  • share
  • Twitter
  • Facebook
  • LinkedIn
GRAIL unveils validation data of its early-detection multi-cancer test

GRAIL, a renowned biotechnology company which focuses on diagnosing cancer in its early stages, when it can be cured easily, reportedly announced validation data regarding its early-detection multi-cancer blood test was published in the Annals of Oncology.

These data demonstrate that the company’s technology is capable of detecting over 50 cancer types in all stages. This technology has a false positive rate that is very low, even less than one percent, from a single blood draw. After the detection of cancer, this test can also tell which body part is infected with cancer with an accuracy rate of 93%.

Today, most of the deadly cancers have no guideline-suggested screening tests available, and as a consequence, most of the cancers are identified in late stages, when survival chances are very low. Thus, the detection of cancer is early stages is highly crucial since the survival rate is 89%, while if the cancer is diagnosed after its spread, its survival rate decreases to 21%.

The validation data published by the company includes information from its foundational CCGA (Circulating Cell-free Genome Atlas) study, that included over 15,000 participants without or with a cancer diagnosis. In the sub-study reported in the publication, outcomes from the validation set signified that the company’s proprietary targeted methylation technology saw a single low false-positive rate which was less than 1%, or high specificity of 99.3%, for over 50 types of cancer.

Head of R&D, Co-founder and Chief Scientific Officer of GRAIL, Alex Aravanis, M.D., Ph.D., stated that the company believes that early detection of several cancers is capable of reducing the cancer mortality rate. This is a very significant moment in cancer detection. The company has built what it believes to be among the biggest clinical study programs every in the field of genomic medicine, and the new data in Annals of Oncology further help GRAIL’s commitment and approach to scientific and clinical rigor.

Joshua Ofman, MSHS, MD, Chief Medical Officer and Chief of External Affairs of GRAIL stated that the Human Genome Project has herald in the age of precision-based medicine, but the benefits it offers has heavily impacted patients suffering from genetic diseases or particular mutations.

 

Source credit: https://picante.today/latest-news/2020/03/31/139859/grail-announces-validation-of-its-multi-cancer-early-detection-test-published-in-annals-of-oncology/

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Anchal Solanki

Anchal Solanki    

A civil engineer by qualification, Anchal Solanki forayed into the domain of content writing in the midst of her graduation, embarking on the career path of a successful freelancer. Equipped with a short-term experience in market research, Anchal currently writes news...

Read More >>

More News By Anchal Solanki

Saint-Gobain sells €1.54B stake in Sika & ends takeover battles
Saint-Gobain sells €1.54B stake in Sika & ends takeover battles
By Anchal Solanki

Saint-Gobain, the French multinational corporation, has recently sold its stake in Sika, the construction chemicals maker in Switzerland, which amounts to €1.54 billion ($1.69 billion). This leads to an end of one of the most bitter takeover bat...

Vestaspace to launch a constellation of 35 satellites for 5G network
Vestaspace to launch a constellation of 35 satellites for 5G network
By Anchal Solanki

Vestaspace Technology, an Indian manufacturer of nano cube as well as small satellites and a space service provider, has reportedly announced that it plans to launch constellation of over 35 satellites to develop 5G speed network connections as well ...

Comtech finalizes $9.1 million contract for its 5G Xypoint vMLC
Comtech finalizes $9.1 million contract for its 5G Xypoint vMLC
By Anchal Solanki

Comtech Telecommunications Corp., leading firm in providing safe and extremely reliable locations, navigation, communication technologies and public safety recently announced that the Location Technologies Group which is a division of Commercial Solu...